Analyzing NewGenIvf Group (NASDAQ:NIVF) and Co-Diagnostics (NASDAQ:CODX)

Co-Diagnostics (NASDAQ:CODX) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Co-Diagnostics and NewGenIvf Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1	2	1	0	2.00
NewGenIvf Group	1	0	0	0	1.00

Co-Diagnostics currently has a consensus target price of $67.50, suggesting a potential upside of 2,792.03%. Given Co-Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than NewGenIvf Group.

Insider and Institutional Ownership

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Co-Diagnostics and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
NewGenIvf Group	N/A	N/A	N/A

Volatility & Risk

Co-Diagnostics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.

Valuation and Earnings

This table compares Co-Diagnostics and NewGenIvf Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$718,166.00	11.71	-$46.90 million	($15.77)	-0.15
NewGenIvf Group	$4.73 million	0.04	$9.88 million	N/A	N/A

NewGenIvf Group has higher revenue and earnings than Co-Diagnostics.

Summary

NewGenIvf Group beats Co-Diagnostics on 7 of the 12 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.